SRRK
NASDAQScholar Rock Holding Corporation
Price$43.79-1.05 (-2.34%)
01:30 PM07:45 PM
News · 26 weeks71-33%
2025-12-142026-06-07
Mix3190d
- Insider12(39%)
- Earnings9(29%)
- SEC Filings6(19%)
- Other3(10%)
- Analyst1(3%)
Latest news
25 items- INSIDERDirector Flier Jeffrey S. was granted 6,839 shares, increasing direct ownership by 28% to 30,909 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Reed Joshua was granted 6,839 shares, increasing direct ownership by 43% to 22,571 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Brudnick Richard was granted 6,839 shares, increasing direct ownership by 45% to 21,896 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Burow Kristina was granted 6,839 shares, increasing direct ownership by 6% to 117,710 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Gilman Michael was granted 6,839 shares, increasing direct ownership by 12% to 62,055 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Peng Katie was granted 6,839 shares, increasing direct ownership by 21% to 39,747 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERDirector Akkaraju Srinivas was granted 6,839 shares, increasing direct ownership by 32% to 27,971 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- SECScholar Rock Holding Corporation filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders8-K - Scholar Rock Holding Corp (0001727196) (Filer)
- PRScholar Rock to Present at the Goldman Sachs 47th Annual Global Healthcare ConferenceScholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the Goldman Sachs 47th Annual Global Healthcare Conference in Miami, FL on Tuesday, June 9, 2026 at 10:00 a.m. ET. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be availabl
- PRScholar Rock to Present at the 2026 Jefferies Global Healthcare ConferenceScholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the 2026 Jefferies Global Healthcare Conference in New York, NY on Wednesday, June 3, 2026 at 11:40 a.m. ET. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be available for
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding CorporationSCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
- PRScholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Scholar Rock (NASDAQ:SRRK, the "Company")) today announced that the company granted inducement equity awards covering an aggregate of 38,481 shares of its common stock to six newly hired employees, consisting of inducement stock options to purchase an aggregate of 12,061 shares of common stock and inducement restricted stock units, covering an aggregate of 26,420 shares of its common stock. The awards are subject to all terms and conditions and other provisions set forth in the Company's 2022 Inducement Equity Plan (the "Plan") and the award agreements thereunder. The Plan, initially adopted by the Company's board of directors on June 16, 2022, and as amended from time to time, is used
- SECAmendment: SEC Form SCHEDULE 13G/A filed by Scholar Rock Holding CorporationSCHEDULE 13G/A - Scholar Rock Holding Corp (0001727196) (Subject)
- SECSEC Form 10-Q filed by Scholar Rock Holding Corporation10-Q - Scholar Rock Holding Corp (0001727196) (Filer)
- SECScholar Rock Holding Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits8-K - Scholar Rock Holding Corp (0001727196) (Filer)
- PRScholar Rock Reports First Quarter 2026 Financial Results and Recent Business HighlightsFDA accepted apitegromab Biologics License Application (BLA) for treatment of children and adults with spinal muscular atrophy (SMA) with September 30, 2026 Prescription Drug User Fee Act (PDUFA) action date Accepted apitegromab BLA includes two fill-finish facilities, Catalent Indiana LLC (part of Novo Nordisk), and a second U.S.-based facility FDA has completed reinspection of Catalent Indiana; classification of facility expected within 90 days following reinspection, in accordance with FDA guidelines Second fill-finish facility on track to have commercial apitegromab supply in early Q3 2026 Scholar Rock is prepared for U.S. apitegromab launch immediately upon FDA approval, w
- PRScholar Rock to Present at the BofA Securities 2026 Health Care ConferenceScholar Rock (NASDAQ:SRRK), a global biopharmaceutical company dedicated to improving the lives of children and adults with spinal muscular atrophy (SMA) and additional rare, severe, and debilitating neuromuscular diseases by applying its leading platform in myostatin biology to advance musculoskeletal health, today announced that management will present at the BofA Securities 2026 Health Care Conference in Las Vegas, NV, on May 12, 2026 at 8:00 a.m. PT / 11:00 a.m. ET. A live webcast of the event will be available under the "Events and Presentations" page within the Investors section of the Scholar Rock website at http://investors.scholarrock.com. A replay of the webcast will be availabl
- INSIDERDirector Burow Kristina exercised 89,800 shares at a strike of $9.14, increasing direct ownership by 426% to 110,871 units (SEC Form 4)4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- SECSEC Form DEFA14A filed by Scholar Rock Holding CorporationDEFA14A - Scholar Rock Holding Corp (0001727196) (Filer)
- SECSEC Form DEF 14A filed by Scholar Rock Holding CorporationDEF 14A - Scholar Rock Holding Corp (0001727196) (Filer)
- ANALYSTCanaccord Genuity initiated coverage on Scholar Rock with a new price targetCanaccord Genuity initiated coverage of Scholar Rock with a rating of Buy and set a new price target of $62.00
- INSIDERSEC Form 4 filed by Woods Keith4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERSEC Form 4 filed by Vaishnaw Akshay4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERSEC Form 4 filed by Sinha Vikas4 - Scholar Rock Holding Corp (0001727196) (Issuer)
- INSIDERSEC Form 4 filed by Hallal David4 - Scholar Rock Holding Corp (0001727196) (Issuer)
SRRK FAQ
7 questionsWhat does Scholar Rock Holding Corporation do?
Scholar Rock Holding Corporation, a clinical-stage biopharmaceutical company, focuses on the discovery and development of medicines for the treatment of serious diseases in which signaling by protein growth factors plays a fundamental role. The company develops Apitegromab, a novel inhibitor of the activation of latent myostatin that has completed the Phase II clinical trials for the treatment of spinal muscular atrophy; and SRK-181, which is in Phase I clinical trials for the treatment of cancers that are resistant to checkpoint inhibitor therapies, such as anti-PD-1 or anti-PD-L1 antibody...Where does SRRK stock trade?
Scholar Rock Holding Corporation (SRRK) is listed on NASDAQ.What sector and industry is SRRK in?
Scholar Rock Holding Corporation operates in the Health Care sector, Biotechnology: Biological Products (No Diagnostic Substances) industry.When did Scholar Rock Holding Corporation go public?
Scholar Rock Holding Corporation (SRRK) completed its IPO in 2018.What are analysts saying about SRRK?
Scholar Rock Holding Corporation has had 8 recent analyst actions on file. The most recent action was from Canaccord Genuity: Buy on 2026-04-21. Recent price targets range from $4200.00 to $4500.00.What companies are similar to SRRK?
Notable peers in the same industry include AMGN (Amgen Inc.), GILD (Gilead Sciences Inc.), ARGX (argenx SE), RVMD (Revolution Medicines Inc.), BIIB (Biogen Inc.). Compare SRRK side-by-side with any of them on Quantisnow.How can I track SRRK on Quantisnow?
Quantisnow aggregates Scholar Rock Holding Corporation's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow SRRK to receive live email and push alerts on every new disclosure.